The Follow-up Study for the Patients of Illicit Substance Use Disorder

Not Applicable

• Conditions: Substance Use Disorders; Illicit Drug Use

• Registration Number: NCT04426565
• Lead Sponsor: Kaohsiung Kai-Suan Psychiatric Hospital

Brief Summary

The patients will be diagnosed according to DSM-5, the severity of individual substance use disorder will be assessed, and the plan of treatment will be provided. The treatment will be determined by the diagnosis and severity of addiction, the mood or psychiatric comorbidities, the hyperactivity or attention deficit, alcohol addiction, and etc. The motivational enhancement interview, the individual psychotherapy, the group psychotherapy, the family therapy will be provided by our team members. In order to evaluate the efficacy of the different therapy, we will evaluate the psychological and social status of the patients and follow up every 3 months. The efficacy of different treatment will be evaluated according to our study instruments.

Detailed Description

The patients will be diagnosed according to DSM-5, the severity of individual addiction will be assessed, and the plan of treatment will be provided. The treatment will be determined by the diagnosis and severity of addiction, the mood or psychiatric comorbidities, the hyperactivity or attention deficit, alcohol addiction, and etc. The motivational enhancement interview, the individual psychotherapy, the group psychotherapy, the family therapy will be provided by our team members. In order to evaluate the efficacy of the different therapy, we will evaluate the psychological and social status of the patients and follow up every 3 months.

The patients will be received the basic physiological assessment, the chest X-ray, electrocardiogram, liver and renal function, hematology test, urine screening for addictive substances, screening for blood infectious diseases (including hepatitis B, C and HIV infection) will be included.

Besides, the Drug Abuse Screen Test (DAST), the Severity of Dependence Scale (SDS), the Reliability of Readiness to Change Questionnaire, the Opiate Treatment Index (OTI), drug Avoidance Self-Efficacy Scale (DASES), the Family APGAR score, The brief version of the World Health Organization Quality of Life instrument (WHOQOL-BREF Taiwan version), Chinese health questionnaire (CHQ), parental bonding instrument (PBI), Toronto Alexithymia Scale (TAS), Brief Symptom Rating Scale (BSRS-5), Chinese version of Adult ADHD Self-Report Scale (ASRS-V1. 1), Becker Depression Scale (BDI) and Becker Anxiety Scale (BAI) will be evaluated every 3 months after receiving our treatment.

Study Timeline

• Study Start: 2020-05-01
• Study First Submitted: 2020-05-19
• Status Verified: 2020-06
• Study First Submitted QC: 2020-06-08
• Last Update Submitted: 2020-06-08
• Study First Posted: 2020-06-11
• Last Update Posted: 2020-06-11
• Primary Completion: 2021-12-30
• Study Completion: 2022-09-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Patients with illicit substance use disorder diagnosed by DSM-5

Exclusion Criteria

The age of the patient is below 20 years old or above 65 years old, the patients cannot cooperate with the tools of investigation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
The World Health Organization Quality of Life instrument (WHOQOL-BREF Taiwan version)	9 months	The instrument has four dimension and higher scores mean a better outcome.
Becker Depression Scale	9 months	The value is from 0 to 63, and higher scores mean a worse outcome.
Becker Anxiety Scale	9 months	The value is from 0 to 63, and higher scores mean a worse outcome.
The severity of substance use used by the Severity of Dependence Scale	9 months	The value is from 0 to 15, and higher scores mean a worse outcome.

Trial Locations

Locations (1)

Kaohsiung Municipal Kai-Syuan Psychiatric Hospital; 🇨🇳 Kaohsiung, Taiwan